Placebo vaginal gel

DRUG5 trials

Sponsors

Juniper Pharmaceuticals, Inc., University of Rochester, Università degli Studi dell'Insubria, University of Washington, Wake Forest University Health Sciences

Conditions

Herpes Simplex Type IIInfertilityLabor, PrematurePregnancyVaginitis

Phase 2

Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by Vaginitis

Università degli Studi dell'InsubriaVaginitis

Start: 2011-09-30End: 2014-12-31Target: 60Updated: 2013-06-21

Phase 3

Vaginal Progesterone to Reduce the Risk of Another Preterm Birth

CompletedNCT00086177

Juniper Pharmaceuticals, Inc.Pregnancy

Start: 2004-04-30End: 2009-03-31Updated: 2010-08-19

Phase 4

Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

CompletedNCT01448616

University of WashingtonHerpes Simplex Type II

Start: 2012-02-29End: 2015-06-30Updated: 2023-02-16

Sexual Absorption of Vaginal Progesterone

CompletedNCT01959464

Wake Forest University Health SciencesInfertility, Pregnancy

Start: 2008-11-30End: 2010-09-30Updated: 2022-04-22

Unknown Phase

Vaginal Progesterone as a Treatment for Women Active Preterm Labor

WithdrawnNCT01206998

University of RochesterLabor, Premature

Start: 2010-07-31End: 2010-08-31Updated: 2012-10-01

Related Papers

Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial

The Journal of Infectious Diseases2015-06-0417 citations

Sexual Absorption of Vaginal Progesterone: A Randomized Control Trial

International Journal of Endocrinology2015-01-0140 citations